Alkermes plc
ALKSAlkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
Drugs in Pipeline
32
Phase 3 Programs
21
Upcoming Catalysts
5
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
5 upcoming, 1 past
How ALKS's past catalysts played out
ALKS 2680 Dose 3
Narcolepsy Type 2
Olanzapine
Schizophrenia
Medisorb naltrexone 380 mg
Opiate Dependence
Medisorb naltrexone 190 mg
Alcohol Dependence
High Dose ALKS 5461
Major Depressive Disorder
ALKS 9072, Low Dose
Schizophrenia
VIVITROL 380 mg
Alcohol Dependence
ALKS 5461
Major Depressive Disorder
ALKS 9072
Schizophrenia
NTX/BUP
Opioid Use Disorder
ALKS 9072, Low
Schizophrenia
Oral naltrexone 50 mg
Alcoholism
ALKS 2680, 4mg
Narcolepsy Type 1
Naltrexone
Opioid Use Disorder
ALKS 2680 Dose 2
Narcolepsy Type 1
ALKS 2680 Dose 1
Narcolepsy Type 1
VIVITROL® 380 mg
Opiate Dependence
Paliperidone Palmitate
Schizophrenia
ALKS 3831
Schizophrenia
ALK3831
Schizophrenia
OLZ/SAM
Schizophrenia
N1539
Hysterectomy
Samidorphan (Low Dose)
Schizophrenia
Motrin
Dental Pain
Samidorphan + olanzapine (ALKS 3831)
Schizophrenia
TrIP-2D
Chronic Obstructive Pulmonary Disease (COPD)
RDC-1036 (ALKS 37)
Opioid-induced Constipation
ALKS 37
Opioid-induced Constipation
RDC-0313 (ALKS 33)
Binge Eating Disorder
ALKS33 (RDC-0313) (1 mg)
Alcohol Dependence
ALKS 2680
Narcolepsy Type 2
Medisorb naltrexone 75 mg
Opiate Dependence
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ALKS 2680 Dose 3 | Phase 3 | Narcolepsy Type 2 | - | - |
Olanzapine | Phase 3 | Schizophrenia | - | - |
Medisorb naltrexone 380 mg | Phase 3 | Opiate Dependence | - | - |
Medisorb naltrexone 190 mg | Phase 3 | Alcohol Dependence | - | - |
High Dose ALKS 5461 | Phase 3 | Major Depressive Disorder | - | - |
ALKS 9072, Low Dose | Phase 3 | Schizophrenia | - | - |
VIVITROL 380 mg | Phase 3 | Alcohol Dependence | - | - |
ALKS 5461 | Phase 3 | Major Depressive Disorder | - | - |
ALKS 9072 | Phase 3 | Schizophrenia | - | - |
NTX/BUP | Phase 3 | Opioid Use Disorder | - | - |
ALKS 9072, Low | Phase 3 | Schizophrenia | - | - |
Oral naltrexone 50 mg | Phase 3 | Alcoholism | - | - |
ALKS 2680, 4mg | Phase 3 | Narcolepsy Type 1 | - | - |
Naltrexone | Phase 3 | Opioid Use Disorder | - | - |
ALKS 2680 Dose 2 | Phase 3 | Narcolepsy Type 1 | - | - |
ALKS 2680 Dose 1 | Phase 3 | Narcolepsy Type 1 | - | - |
VIVITROL® 380 mg | Phase 3 | Opiate Dependence | - | - |
Paliperidone Palmitate | Phase 3 | Schizophrenia | - | - |
ALKS 3831 | Phase 3 | Schizophrenia | - | - |
ALK3831 | Phase 3 | Schizophrenia | - | - |
OLZ/SAM | Phase 3 | Schizophrenia | - | - |
N1539 | Phase 2 | Hysterectomy | - | - |
Samidorphan (Low Dose) | Phase 2 | Schizophrenia | - | - |
Motrin | Phase 2 | Dental Pain | - | - |
Samidorphan + olanzapine (ALKS 3831) | Phase 2 | Schizophrenia | - | - |
TrIP-2D | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
RDC-1036 (ALKS 37) | Phase 2 | Opioid-induced Constipation | - | - |
ALKS 37 | Phase 2 | Opioid-induced Constipation | - | - |
RDC-0313 (ALKS 33) | Phase 2 | Binge Eating Disorder | - | - |
ALKS33 (RDC-0313) (1 mg) | Phase 2 | Alcohol Dependence | - | - |
ALKS 2680 | Phase 2 | Narcolepsy Type 2 | - | - |
Medisorb naltrexone 75 mg | Phase 2 | Opiate Dependence | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Alkermes plc's drug pipeline?→
CatalystAlert tracks 32 drug candidates in Alkermes plc's (ALKS) pipeline across Phase 3, Phase 2. Its lead program is ALKS 2680 Dose 3 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alkermes plc's next FDA catalyst?→
Alkermes plc's (ALKS) next tracked catalyst is a Phase 3 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALKS biotech catalysts?→
Add ALKS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alkermes plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.